Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL245730 | 1.00 | — | — | |
| Ethane SCHEMBL6711452 | 0.96 | — | — | |
| Iodide SCHEMBL31361258 | 0.96 | — | — | |
| Ammonia Solution, Strong SCHEMBL3830975 | 0.96 | — | — | |
| SCHEMBL4872069 | 0.89 | — | — | |
| SCHEMBL302060 | 0.84 | — | — | |
| SCHEMBL7148382 | 0.84 | — | — | |
| SCHEMBL732233 | 0.84 | — | — | |
| SCHEMBL10239392 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28287498 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | UNIV YALE (US) | 2017-03-30 | — | — | US | disclosed |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | UNIV YALE (US) | 2016-09-22 | — | — | US | disclosed |
| US-9346846-B1 | Anti-cancer compounds and methods for treating cancer | YALE UNIVERSITY (US) | 2016-05-24 | — | — | US | disclosed |
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | YALE UNIVERSITY | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087609-A1 | CYTOTOXIC-DRUG DELIVERING MOLECULES TARGETING HIV (CDM-HS), CYTOTOXIC ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS AND METHODS OF USE | CD4, HAVCR2, CD74 | LMNA 3978/4885 |
| US-20170087148-A1 | TLR-AGONIST-CONJUGATED ANTIBODY RECRUITING MOLECULES (TLR-ARMs) | TLR3, TLR4, TLR1 | LMNA 4420/4885 |
| US-20160271156-A1 | ANTI-CANCER COMPOUNDS AND METHODS FOR TREATING CANCER | POLM, FOLR1, TYMP | LMNA 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.